Drugs News and Research

RSS

Secondary prevention program may reduce risks after heart attack

An intensive, comprehensive, long-term secondary prevention program lasting up to three years after cardiac rehabilitation appears to reduce the risk of a second non-fatal heart attack and other cardiovascular events, according to a report in the November 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.

11 Nov 2008

Researchers aim to over-stress already taxed mantle cell lymphoma cells

Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.

11 Nov 2008

Latest research on diagnosis and treatment of allergic diseases

Researchers are presenting more than 450 abstracts on investigational findings in the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Seattle, Nov. 6-11. Following are highlights of some key studies on asthma.

11 Nov 2008

New performance measures on performance measurement and reperfusion therapy

The ACC/AHA 2008 Task Force on Performance Measures' Statement on Performance Measurement and Reperfusion Therapy will webpost on Monday, November 10 at 2 pm ET.

11 Nov 2008

New analysis of the mechanisms that drive evolution in viruses and bacteria

It sounds like a science fiction movie: A killer contagion threatens the Earth, but scientists save the day with a designer drug that forces the virus to mutate itself out of existence.

11 Nov 2008

Data expands the clinical utility of deCODE tests for heart attack, atrial fibrillation and stroke

Several presentations by deCODE genetics scientists and independent researchers at the American Heart Association Scientific Sessions 2008 being held at the New Orleans Convention Center from November 8 to12 are expected to expand upon the clinical utility of evaluating individual risk of heart attack, or atrial fibrillation and stroke, respectively, by measuring the genetic markers that are the basis of the deCODE MI and deCODE AF tests.

11 Nov 2008

Trial of investigational drug for treatment of advanced heart failure

UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure.

10 Nov 2008

Antibacterial drug use increases at academic medical centers

Antibacterial drug use appears to have increased at academic medical centers between 2002 and 2006, driven primarily by greater use of broad-spectrum agents and the antibiotic vancomycin, according to a report in the Nov. 10 issue of Archives of Internal Medicine , one of the JAMA/Archives journals.

10 Nov 2008

1918 Spanish flu records could hold the key to solving future pandemics

Ninety years after Australian scientists began their race to stop the spread of Spanish flu in Australia, University of Melbourne researchers are hoping records from the 1918 epidemic may hold the key to preventing future deadly pandemic outbreaks.

10 Nov 2008

Rheumatoid arthritis drugs too slow to stop damage

A study by New Zealand researchers has questioned the current treatment approaches for rheumatoid arthritis and say they may be too slow in controlling the start of the joint damage the disease causes.

10 Nov 2008

Resverlogix Corp shows RVX-208 demonstrates increase in functional HDL particles

Resverlogix Corp. has announced key scientific data was presented in an oral presentation highlighting the novel features of RVX-208 at the American Heart Association Scientific Meeting. The presentation titled "Compound RVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early Human Trials" was presented by Dr. Jacques Genest.

10 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Chaotic vasculature hinders tumor growth

Dense networks of blood vessels thought to spur cancer's growth could actually hinder rather than promote tumor progression, according to a new study at the University of California, San Diego.

10 Nov 2008

Scientists engineer immune cells to act as "bionic assassins" that see through HIV's many disguises

HIV is a master of disguise, able to rapidly change its identity and hide undetected in infected cells.

10 Nov 2008

New hybrid technology for disease prevention

The earlier cancer is diagnosed, the better the chance of effecting a cure.

10 Nov 2008

New research on chronic corticosteroid use

An analysis of large population databases has recently yielded important findings about chronic corticosteroid use.

10 Nov 2008

Further evidence that angiogenesis drugs can be much more effective when combined with chemotherapy

Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein.

10 Nov 2008

Discovery of gene that regulates mold's resistance to drugs

Montana State University scientists concerned about lethal mold infections have found a gene that regulates the mold's resistance to drugs.

8 Nov 2008

Behavioral therapy helps overcome depression in kidney disease patients on dialysis

Depression is common among individuals on dialysis for kidney disease, but behavioral therapy can significantly improve their quality of life, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

8 Nov 2008

Study compares survival following different heart disease treatments in patients with ESRD

For patients with end stage renal disease (ESRD) on dialysis who also must be treated for heart disease, stents provide the best one-year survival compared with other revascularization treatments, but bypass surgery provides the best long-term survival, according to a paper being presented at the American Society of Nephrology's 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

7 Nov 2008